INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/005152

CLASSIFICATION OF SUBJECT MATTER
Int.Cl² C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02, A61P43/00, A61R43/95

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl7 C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02, A61P43/00, A61K39/395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, BIOSIS/WPI(DIALOG), SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Form PCT/ISA/210 (second sheet) (January 2004)

Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Hudson P.J. et al., High avidity scFv multimers; diabodies and triabodies, J.Immunol.Methods, 1999, Vol.231, pages 177 to 189	1-14
Kortt A.A. et al., Dimeric and trimeric anti bodies: high avidity scFvs for cancer target ing, Biomol.Eng., 2001, Vol.18, pages 95 to 108	1-14
Xiong D. et al., Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody, Cancer Lett., 2002, Vol.177, pages 29 to 39	1-14
	Hudson P.J. et al., High avidity scFv multimers; diabodies and triabodies, J.Immunol.Methods, 1999, Vol.231, pages 177 to 189 Kortt A.A. et al., Dimeric and trimeric anti bodies: high avidity scFvs for cancer target ing, Bicmol.Eng., 2001, Vol.18, pages 95 to 108 Xiong D. et al., Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody, Cancer Lett., 2002,

×	Further documents are listed in the continuation of Box C.	See patent family annex.
"A"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance	"I" later document published after the international filing date or priority date and not in conflict with the application but eited to understand the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date document which may throw doubts on priority elaim(s) or which is	"X" document of particular relevance; the claimed invention cannot be considered novel or eannot be considered to involve an inventive step when the document is taken alone
-	cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the elaimed invention cannot be considered to involve an inventive step when the document is
"O"	document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than	re, use, exhibition or other means combined with one or more other such documents, such combination
•	the priority date claimed	"&" document member of the same patent family
	of the actual completion of the international search 05 July, 2004 (05.07.04)	Date of mailing of the international search report 20 July, 2004 (20.07.04)
	and mailing address of the ISA/ Japanese Patent Office	Authorized officer
Facci	mile No	Telephone No.

INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2004/005152

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MATSUOKA S. et al., A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement, J.Exp.Med., 1995, Vol.181, pages 2007 to 2015	1-14
Y	Fayen J. et al., Negative signaling by anti- RLA class I antibodies is dependent upon two triggering events, Int.Immunol., 1998, Vol.10, pages 1347 to 1358	1-14
Y	Woodle E.S. et al., Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated path way, J.Immunol., 1997, Vol.158, pages 2156 to 2164	1-14
Y	Tahtis k. et al., Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 38193 diabody and F(ab') (2), constructs in a breast carcinoma xenograft model, Clin.Cancer Res., 2001, Vol.7, pages 1061 to 1072	1-14
Y	Rossi E.A. et al., Development of new multi valent-bispecific agents for pretargeting tumor localization and therapy, Clin.Cancer Res., 2003, Vol.9, pages 3886S to 3896S	1-14
Е, Х	WO 04/033499 A1 (Chugai Pharmaceutical Co., Ltd.), 22 April, 2004 (22.04.04), Full text (Family: none)	1-14